Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Annals of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdn671PMID 19074215
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

  2008cited by this paper
• Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria

  2007cited by this paper
• Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma.

  2007cited by this paper
• 18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

  2007cited by this paper
• Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis

  2007cited by this paper
• 18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review

  2007cited by this paper
• 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.

  2006cited by this paper
• Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

  2005influential reference
• A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphoma

  2005cited by this paper
• FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

  2005cited by this paper
• ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.

  2005cited by this paper
• Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

  2005cited by this paper
• Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study.

  2005cited by this paper
• Systematic Review of 18F-Fluorodeoxyglucose Positron Emission Tomography for Post-Treatment Evaluation of Malignant Lymphoma.

  2005cited by this paper
• [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

  2005cited by this paper
• Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues

  2003cited by this paper
• Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

  2002cited by this paper
• Pathology and genetics: Tumours of haematopoietic and lymphoid tissues

  2001cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Prediction of immunochemotherapy response for diffuse large B‐cell lymphoma using artificial intelligence digital pathology

  2024cites this paper
• Application of interim PET-CT in first-line treatment decision-making for lymphoma

  2023cites this paper
• Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial

  2022cites this paper
• PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.

  2021cites this paper
• Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells

  2021cites this paper
• 18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study

  2021cites this paper
• ΔSUVmax for interim PET in DLBCL: old is new.

  2020cites this paper
• Significance of bulky mass and residual tumor—Treated with or without consolidative radiotherapy—To the risk of relapse in DLBCL patients

  2020cites this paper
• Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial.

  2020cites this paper
• Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV- associated, B-cell non-Hodgkin's lymphoma.

  2020cites this paper
• Interim response in diffuse large B cell lymphoma on CT: what is the optimal size reduction (ΔSPD) for predicting outcome?

  2020cites this paper
• Prognostic value of 18F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation

  2019cites this paper
• Lymphomes

  2019cites this paper
• PET beyond Deauville in diffuse large B-cell lymphoma

  2019cites this paper
• Diffusion-Weighted and Perfusion-Weighted MRI to Evaluate Therapeutic Response in Lymphoma: A Comparison with FDG-PET/CT

  2018cites this paper
• [Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation].

  2018cites this paper
• Tratamiento del linfoma difuso de células B grandes (LDCBG) en estadios avanzados

  2017cites this paper
• Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin’s lymphoma

  2017cites this paper
• R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients

  2017cites this paper
• Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?

  2017cites this paper
• Focus On 1 : Emerging Paradigms in PET

  2017cites this paper
• Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

  2017cites this paper
• FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.

  2017influential citation
• Prognostic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation.

  2017cites this paper
• Diagnostic applications of nuclear medicine: Lymphomas

  2017cites this paper
• Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors

  2016cites this paper
• Immunohistochemi-NCCN Diffuse Large B-Cell Lymphoma Version 1 . 2016 Clinical Practice Guidelines in Oncology

  2016cites this paper
• Aggressive B-Cell Lymphomas

  2016cites this paper
• Clinical approach to diffuse large B cell lymphoma.

  2016cites this paper
• Diffuse Large B-Cell Lymphoma Version 1.2016.

  2016cites this paper
• Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy

  2016cites this paper
• Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.

  2016cites this paper
• Sarcoidosis and lymphoma: a comparative study.

  2015cites this paper
• Utility of interim and end‐of‐treatment PET/CT in peripheral T‐cell lymphomas: A review of 124 patients

  2015cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) ® Non-Hodgkin ’ s Lymphomas

  2015cites this paper
• Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma

  2015cites this paper
• Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.

  2015cites this paper
• Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis.

  2015cites this paper
• Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma

  2015cites this paper
• Treatment approach to newly diagnosed diffuse large B-cell lymphoma.

  2015cites this paper
• Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas

  2015cites this paper
• Current role of FDG PET/CT in lymphoma

  2014cites this paper
• Intensification treatment based on early FDG‐PET in patients with high‐risk diffuse large B‐cell lymphoma: a phase II GELTAMO trial

  2014cites this paper
• Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

  2014cites this paper
• The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients

  2014cites this paper
• Lymphoma: Management Using PET/CT

  2014cites this paper
• Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.

  2014cites this paper
• Clinical Implications of the Role of 18FDG-PET/CT in Malignant Lymphomas

  2014cites this paper
• Identifying response to therapy in longitudinal PET imaging studies

  2014cites this paper
• R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma

  2014cites this paper
• Role of PET in Lymphoma

  2014cites this paper
• Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma

  2013cites this paper
• Adults with palpable neck mass: Evidence-based neuroimaging

  2013cites this paper
• PET/CT in malignant lymphoma: basic information, clinical application, and proposal

  2013cites this paper
• The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.

  2013cites this paper
• Interim FDG-PET in Diffuse Large B-Cell Non-Hodgkin’s Lymphoma: A Meta-Analysis

  2013cites this paper
• [Eight-year experience in treating aggressive mediastinal large B-cell lymphomas].

  2013cites this paper
• Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy

  2012cites this paper
• Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

  2012cites this paper
• The Evolving Role of Medical Imaging in Lymphoma Management: The Clinician's Perspective.

  2012cites this paper
• Early Interim PET Scans in Diffuse Large B-Cell Lymphoma: Can There Be Consensus About Standardized Reporting, and Can PET Scans Guide Therapy Choices?

  2012cites this paper
• Clinical Investigation : Lymphoma Combined Modality Treatment for PET-Positive Non-Hodgkin Lymphoma : Favorable Outcomes of Combined Modality Treatment for Patients With Non-Hodgkin Lymphoma and Positive Interim or Postchemotherapy FDG-PET

  2012cites this paper
• FDG-PET/CT based response-adapted treatment

  2012cites this paper
• The Evolving Role of Medical Imaging in Lymphoma The Clinician's Perspective

  2012cites this paper
• Sarcoidosis mimicking recurrent lymphoma

  2012cites this paper
• Positron emission tomographic scans in lymphoma: convention and controversy.

  2012cites this paper
• My treatment approach to patients with diffuse large B-cell lymphoma.

  2012cites this paper
• SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

  2011cites this paper
• Impact of FDG-PET/CT in the management of lymphoma

  2011cites this paper
• Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.

  2011cites this paper
• Role of functional imaging in the management of lymphoma.

  2011cites this paper
• Use of PET/CT to evaluate response to therapy in lymphoma.

  2011cites this paper
• Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

  2011cites this paper
• FDG-PET/CT in lymphoma.

  2011cites this paper
• Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma ( CSLL-1 Follicular Lymphoma ( FOLL-1 Mantle Cell Lymphoma ( MANT-1 Diffuse Large B-Cell Lymphoma ( BCEL-1 Burkitt Lymphoma ( BURK-1 Lymphoblastic

  2010cites this paper
• INTERIM 18 F-FDG PET IN LYMPHOMA: FROM PREDICTION OF RESPONSE TO RESPONSE-ADAPTED THERAPY. A NEW PARADIGM.

  2010cites this paper
• Non-Hodgkin's LymphomasPractice Guidelines in Oncology TM

  2010cites this paper
• Non-Hodgkin's lymphomas.

  2010cites this paper
• The evolving role of 18F-FDG PET scans in patients with aggressive non-Hodgkin’s lymphoma

  2010cites this paper
• A decade of progress in lymphoma: advances and continuing challenges.

  2010cites this paper
• The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma.

  2010cites this paper
• Improving Outcomes for Patients with Diffuse Large B‐cell Lymphoma

  2010cites this paper
• Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy

  2010cites this paper
• Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.

  2010cites this paper
• Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand?

  2009cites this paper
• S.J. Horning Biomarkers in diffuse large B-cell lymphoma

  2009cites this paper
• Biomarkers in diffuse large B-cell lymphoma

  2009cites this paper